Vanda Pharmaceuticals Inc (Nasdaq: VNDA), a global biopharmaceutical company, announced its financial results for the full year ended 31 December 2020 on Wednesday.
The company reported income before taxes at USD31.7m in 2020 compared to USD29m in 2019.
The firm posted net income of USD23.3m in 2020, compared to net income of USD115.6m in 2019. It reported diluted net income per share of USD0.42 in 2020 compared to diluted net income per share of USD2.11 in 2019.
'I am very proud of the significant accomplishments we realised during this challenging year,' said Mihael H Polymeropoulos, Vanda's MD, president and CEO.
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Perrigo announces quarterly dividend increase
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva
Biosenic finalises agreement with Phebra for oral arsenic troxide development